Study Title: Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data
Citation: Hidalgo et al., 2022 · J Basic Clin Physiol Pharmacol
What the Study Found: This review examines basic and clinical evidence on (−)-epicatechin and EGCG for nonalcoholic fatty liver disease (NAFLD). It highlights (−)-epicatechin’s ability to promote mitochondrial biogenesis, improve lipid metabolism, and exert anti-inflammatory, antioxidant, and antifibrotic effects. These actions collectively support better liver energy handling and reduced disease progression.
What this means in real life: The liver depends on healthy mitochondria to break down fats and manage energy; when mitochondrial function declines, fat builds up and inflammation follows. This review shows that (−)-epicatechin can enhance mitochondrial biogenesis and lipid metabolism in the liver, offering a practical nutraceutical route to slow NAFLD. At Mitozz we focus on mitochondrial health because supporting cellular energy production helps the liver stay resilient under modern metabolic stress.
関連コンテンツ
- Curious how mitochondrial health affects liver fat and metabolic balance? → Mitochondrial Health and Fatty Liver
- Want to understand how cellular energy shapes metabolic resilience? → Mitochondrial Dysfunction and Obesity: What’s the Connection?
- Looking for ways to support mitochondrial function in daily life? → How to Repair and Maintain Mitochondrial Health Naturally